SGMO — Sangamo Therapeutics, Inc.

Sangamo Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

   • Sangamo's common stock transitioned to the OTCQB Venture Market after receiving a delisting determination from NASDAQ due to noncompliance with minimum bid requirements. The company plans to appeal this decision in June.
   • The financial position remains a concern, with ongoing efforts to secure additional capital to support operations and development initiatives.

2. Strategic Updates and Business Highlights:

   • The rolling submission of the Biologics License Application (BLA) for ST-920, a gene therapy for Fabry disease, is progressing, with the first two modules submitted and the Chemistry, Manufacturing, and Controls (CMC) module in development.
   • Sangamo has received FDA affirmation that 104-week data can be submitted for traditional approval without the need for an additional confirmatory study, which is a significant regulatory milestone.
   • The company showcased advancements in its neurology pipeline, including the activation of six clinical sites for the Phase I/II STAND study evaluating ST-503 for small fiber neuropathy and progress on ST-506 for prion disease.

3. Forward Guidance and Outlook:

   • Sangamo anticipates completing the BLA submission for ST-920 as early as summer 2026, contingent on securing adequate funding.
   • The company is actively pursuing strategic opportunities to raise capital and maximize asset value, indicating a proactive approach to financial stability.

4. Bad News, Challenges, or Points of Concern:

   • The transition to the OTCQB Venture Market reflects ongoing financial challenges and the need for capital, raising concerns about Sangamo's operational viability.
   • The delisting from NASDAQ may impact investor confidence and market perception, potentially affecting future fundraising efforts.

5. Notable Q&A Insights:

   • Management confirmed that they are approximately three-fifths through the rolling submission process and are working on data cleaning for the 104-week dataset, with plans to disclose data at an appropriate time.
   • There was a positive outlook on the durability of treatment effects, with patients showing stability beyond five years and some off enzyme replacement therapy for over three years.
   • The FDA's recent affirmation is expected to enhance business development discussions, although management refrained from disclosing specific details about ongoing negotiations related to the Fabry program.

Overall, while Sangamo has made significant progress in its clinical programs and regulatory interactions, financial challenges and the recent stock market transition pose risks that the company must navigate carefully.